LTFS
LXRX icon

Ladenburg Thalmann Financial Services’s Lexicon Pharmaceuticals LXRX Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$4K Sell
1,043
-1,202
-54% -$4.63K ﹤0.01% 4863
2019
Q3 		$7K Hold
2,245
– – ﹤0.01% 4543
2019
Q2 		$14K Sell
2,245
-3,966
-64% -$23.7K ﹤0.01% 4264
2019
Q1 		$34K Buy
6,211
+163
+3% +$990 ﹤0.01% 3662
2018
Q4 		$41K Sell
6,048
-317
-5% -$2.57K ﹤0.01% 3399
2018
Q3 		$68K Sell
6,365
-258
-4% -$2.96K ﹤0.01% 3118
2018
Q2 		$57K Hold
6,623
– – ﹤0.01% 3179
2018
Q1 		$57K Buy
6,623
+1,159
+21% +$10.7K ﹤0.01% 3179
2017
Q4 		$54K Buy
5,464
+4,412
+419% +$45.8K ﹤0.01% 3158
2017
Q3 		$13K Sell
1,052
-1,828
-63% -$27K ﹤0.01% 3935
2017
Q2 		$47K Buy
2,880
+1,824
+173% +$28.2K ﹤0.01% 3071
2017
Q1 		$15K Sell
1,056
-300
-22% -$4.45K ﹤0.01% 3734
2016
Q4 		$19K Buy
1,356
+3
+0.2% +$48 ﹤0.01% 3509
2016
Q3 		$24K Sell
1,353
-557
-29% -$8.96K ﹤0.01% 3274
2016
Q2 		$27K Buy
1,910
+14
+0.7% +$190 ﹤0.01% 3134
2016
Q1 		$23K Buy
1,896
+510
+37% +$5.35K ﹤0.01% 3163
2015
Q4 		$18K Buy
1,386
+386
+39% +$4.75K ﹤0.01% 3297
2015
Q3 		$11K Buy
+1,000
New +$10.9K ﹤0.01% 3465
2015
Q2 		– Sell
-143
Closed -$1K – 4709
2015
Q1 		$1K Sell
143
-3
-2% -$20 ﹤0.01% 4431
2014
Q4 		$1K Buy
146
+3
+2% +$24 ﹤0.01% 4213
2014
Q3 		$1K Sell
143
-714
-83% -$7.62K ﹤0.01% 3805
2014
Q2 		$10K Sell
857
-1,000
-54% -$10.7K ﹤0.01% 3076
2014
Q1 		$22K Sell
1,857
-1,714
-48% -$21.9K ﹤0.01% 2508
2013
Q4 		$45K Hold
3,571
– – ﹤0.01% 1982
2013
Q3 		$60K Hold
3,571
– – ﹤0.01% 1698
2013
Q2 		$54K Buy
+3,571
New +$54.3K ﹤0.01% 1692

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Ladenburg Thalmann Financial Services's LXRX Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services reduced its Lexicon Pharmaceuticals (LXRX) stake by 54% in Q4 2019, selling an estimated $4.63K and leaving 1,043 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #4863.

Ladenburg Thalmann Financial Services first reported a position in LXRX in Q2 2013 and has held it in 26 quarters since. The position peaked at $68K in Q3 2018. 115 funds tracked by Wall St. Rank hold LXRX as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 1,043 shares of Lexicon Pharmaceuticals worth $4K as of Q4 2019.
  • Ladenburg Thalmann Financial Services sold 1,202 Lexicon Pharmaceuticals shares in Q4 2019, an estimated $4.63K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #4863 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 26 quarters since.
  • Ladenburg Thalmann Financial Services's Lexicon Pharmaceuticals position peaked at $68K in Q3 2018.
  • 115 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.